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Two recent publications have demonstrated how
delivering CRISPR nucleases provides a promising
solution to the growing problem of bacterial
antibiotic resistance.plasmids [5-7]. Original work from the Marraffini groupThe problem(s) with antibiotics
Once the beacon of modern medicine, antibiotics now
threaten to be its undoing. These miracle molecules were
originally heralded for their remarkable ability to cure a
myriad of microbial infections. However, their overuse in
medicine and abuse in animal agriculture has led to the
rise of multidrug-resistant pathogens that are increasingly
tolerant to our current antibiotic arsenal. Even worse,
these same antibiotics indiscriminately kill beneficial bac-
teria along with the pathogens. The consortia of indigen-
ous residents occupying our internal and external bodily
surfaces - our microbiome - have been widely implicated
in human health, and their disruption by antibiotics is
thought to have equally devastating effects. Accordingly,
there is a need for novel antimicrobials that can bypass
common modes of multidrug resistance while being
selective for individual strains. Two recent papers in
Nature Biotechnology by Bikard et al. [1] and Citorik et al.
[2] offer a promising solution to the problem of antibiotic
resistance by using CRISPR (‘clustered regularly interspaced
short palindromic repeats’)-Cas (‘CRISPR associated’)
systems.
CRISPR-Cas systems are adaptive immune systems
native to bacteria and archaea that employ CRISPR RNAs
to recognize and destroy complementary nucleic acids
(Figure 1) [3]. The discovery of one type of CRISPR-Cas
system that requires only a single protein for CRISPR-
RNA-directed DNA binding and cleavage (Cas9) quickly
led to numerous applications, the most popular of which* Correspondence: cbeisel@ncsu.edu
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org/publicdomain/zero/1.0/) applies to the datahas been genome editing [4]. However, less explored is the
potential of these systems to serve as sequence-specific
antimicrobials. Early work demonstrated that CRISPR-Cas
systems are cytotoxic following incidental self-targeting
of the bacterial genome and that they can be used to
immunize cells against the spread of multidrug-resistant
even suggested that CRISPR-Cas systems could be used
for the sequence-specific killing of bacteria [8]. Subse-
quently, we recently reported the concept of CRISPR-Cas
systems as programmable antimicrobials [9], demonstrat-
ing that both heterologous and endogenous systems could
selectively kill bacterial species and strains. Intriguingly,
every sequence in the genome that was targeted led to kill-
ing, suggesting that virtually any genomic location could
be a distinct target for CRISPR-based antimicrobials [9].
However, an appropriate delivery vehicle was lacking.
Now, Bikard et al. [1] and Citorik et al. [2] tackle this chal-
lenge as the next major step towards deploying CRISPR-
Cas systems as antimicrobial agents.CRISPR-Cas9 to go
For delivery, both studies employed phagemids - plasmids
with phage packaging signals - equipped with sequences en-
coding the Streptococcus pyogenes Cas9 nuclease, a designed
CRISPR RNA and a trans-activating crRNA (tracrRNA) for
CRISPR RNA processing [10]. The beauty of this approach
is that phages have already evolved to inject their genetic
material into the host bacterium.
The difference between the studies was that Bikard and
colleagues [1] used Staphylococcus aureus and its temper-
ate phage ϕNM1, whereas Citorik and colleagues [2] used
Escherichia coli with its filamentous phage M13. Both spe-
cies are clinically relevant because of their documented
antibiotic resistance - particularly multidrug-resistant S.
aureus (MRSA). The attraction of the phagemid approach
rather than use of the phage itself was that new CRISPR
RNA sequences could be readily cloned into the phagemid
backbone. The packaged phagemids were then employed
to target the genome, which led to extensive and rapid. The licensee has exclusive rights to distribute this article, in any medium, for 12
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Figure 1 Delivering CRISPR-Cas9 for targeted killing and plasmid removal. Left: phages are engineered to encode the Cas9 nuclease, a
trans-activating crRNA (tracrRNA) and an array of plasmid-targeting or genome-targeting CRISPR RNAs. The CRISPR RNAs are designed to target
unique sequences in the bacterial chromosome or in harbored plasmids. Right: injection of the phage DNA into a mixed population of bacteria
leads to removal (here depicted with broken lines) of targeted strains or plasmids without impacting the rest of the population. With further
development, this strategy has the potential to treat multidrug-resistant infections without impacting beneficial microbes, to remove contaminating
microbes from industrial fermentations and to provide further insights into microbial communities.
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packaged phagemid. The phagemids were also employed
to target harbored antibiotic-resistance plasmids, which
led to efficient plasmid removal. Surprisingly, in the study
by Citorik et al. [2], plasmid removal induced killing. This
was traced to the addiction systems of the plasmid that kill
the host cell in the absence of plasmid, offering an indirect
benefit of targeting some mobile elements encoding drug
resistance. Conjugation was also investigated as a means
of delivery [2], although the transfer efficiency was too low
to substantially reduce cell counts.
With any antimicrobial, the immediate question is
how microbes evolve resistance. Remarkably, the survi-
vors did not circumvent targeting - instead they either
did not receive the CRISPR-Cas system, or they received
a defective system, which is in line with previous find-
ings [9]. The consistency of these findings would argue
against the emergence of resistance to CRISPR-Cas-
mediated targeting. Instead, other bottlenecks are likely
to thwart effective targeting, as will be described later in
this article.
Another powerful demonstration of the potential of this
technology utilized mixed bacterial communities. The au-
thors relied on two-member or three-member communi-
ties of genetic variants of the same strain - a step towards
natural communities. In both cases, the authors could
specifically eliminate individual target strains while sparing
non-target strains. Citorik and colleagues were able to
distinguish a single base-pair change between two of
the strains, underscoring the specificity of targeting. By
exploiting the multiplexable nature of CRISPR, the authorsalso demonstrated that the CRISPR RNAs also could be
readily arrayed to concurrently target more than one strain
or plasmid at a time.
To further extend their results, both studies conducted
in vivo experiments. Bikard et al. [1] employed a skin in-
fection model in mice with a co-culture of one targeted
fluorescent strain and one non-targeted non-fluorescent
strain of S. aureus. Citorik et al. [2] employed an infection
model in which larvae of the honeycomb moth Galleria
mellonella were fed enterohemorrhagic E. coli (EHEC)
O157:H7. In both cases, application of the phagemids had
a modest but statistically significant effect on the target
strain - either by reducing the fraction of fluorescent S.
aureus strains occupying the skin of the mouse or by
improving the survival of the flat worms. While there is
room for improvement, these findings offer the first step
towards the in vivo delivery of CRISPR-Cas systems in
clinical and environmental settings.
The path forward
These initial demonstrations open a wide range of appli-
cations for the delivery of CRISPR-based antimicrobials
that are otherwise poorly addressed by traditional anti-
biotics. The primary focus of these studies was treating
multidrug-resistant infections without compromising the
normal flora, either by killing the pathogen or by restor-
ing its susceptibility to antibiotics. However, many more
opportunities exist. For instance, these technologies
might be used to study natural and synthetic microbial
communities, ranging from those populating our digest-
ive tracts to those in the soil. Engineered phages could
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order to study how the whole community responds over
time. Separately, engineered phages could clear heavily
guarded niches. By opening these niches, beneficial or
diagnostic strains could be administered to take hold of
the niche and establish long-term residency in the
community. A third opportunity is using these phages to
prevent the spread of multidrug-resistance markers in
natural environments, thereby stymying the further dis-
semination of resistance. Finally, eliminating contamin-
ation of batch fermentations without compromising the
production host could combat a common and econom-
ically costly industrial problem. New ways of addressing
this issue without discarding the batch could be a major
financial boon across the food, beverage, biotechnology
and therapeutic industries.
With these applications in mind, a major question is
whether use of lytic phages themselves would be sufficient
for the same end. Lytic phages are normally strain-specific,
replicate as part of the killing process, can be readily iso-
lated from the environment and do not necessarily require
any genetic modification. Indeed, lytic bacteriophages are
being actively explored as a means of combating multidrug-
resistant infections and food contamination. One unique
opportunity is incorporating CRISPR-Cas9 into lysogenic
bacteriophages, which would greatly expand the set of
phages that can be employed as antimicrobials. Another
opportunity is using CRISPR-Cas9 to target features that
distinguish otherwise-identical strains, such as a recently
acquired antibiotic-resistance gene. Finally, CRISPR-Cas9
can be readily programmed to target different species,
whereas a new lytic phage would need to be isolated and
characterized.
Hurdles ahead
To truly exploit the capabilities of CRISPR-Cas9, deliv-
ery vehicles are needed that can inject their cargo into
diverse strains. Broad-host-range phages are extremely
rare, and those that are known, at best, infect species
within a single genus. Despite phages serving as the first
model system in molecular biology, little is known about
how to alter or expand their host range. We see this as
an excellent opportunity to interrogate poorly under-
stood elements of phage biology while generating phages
that can infect virtually any host microbe. Alternatively,
nanoparticles or outer-membrane vesicles offer add-
itional promising, yet poorly explored, delivery options.
Using such broad-spectrum delivery vehicles, or any
delivery vehicle for that matter, poses a number of chal-
lenges that will impact the efficacy of the approach. As
evident in these two papers, efficacy dropped substan-
tially in the relatively simple in vivo experiments. The
first challenge is that the vehicle needs to reach the site
of infection in sufficient numbers to deliver the cargointo all possible strains. In natural communities such as
the gut microbiota, this would require the particles to
survive ingestion and reach the approximately 100 tril-
lion cells of the digestive tract in locations of varying
accessibility, which is a formidable challenge. A second
challenge is that appropriate surface receptors would
need to be expressed on the cells for phage infection -
expression levels of these receptors can vary across the
population, depending on the environmental conditions.
Third, once injected into the cell, the DNA must bypass
the defense systems of the host (for example, restriction-
modification systems, native CRISPR-Cas systems) and
lead to sufficient expression of CRISPR-Cas9. Finally, the
targeting sequence must be carefully selected to avoid
incidental killing of other strains, although advances in
next-generation sequencing are providing a wealth of
data for identifying appropriate sequences. Going for-
ward, further efforts will need to tackle each of these
barriers. However, each challenge should be surmount-
able, potentially yielding versatile tools to study and
remodel microbial communities as well as providing
tailored antimicrobials for the treatment of multidrug-
resistant infections.
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